CD86 and neoplasm: Cheng et al. incorporated the tumor antigen peptide OVA257-264 with ClyA protein on the surface of an OMV, thus effectively eliciting maturation and expression of CD80 and CD86 in bone marrow dendritic cells (BMDCs), triggering tumor antigen-specific T-cell immune responses, and markedly attenuating lung metastasis in the B16 melanoma model [130].